A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke

NCT07742098 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

DRUG: NTS-521
OTHER: Placebo Control

Sponsor

NeuroTrauma Sciences, LLC